Oxnard, CA â FOMAT is proud to announce the launch of its new Phase I clinical trials capabilities. This expansion will enhance FOMAT’s ability to provide efficient and high quality services to clients in the pharmaceutical and biotech industries, while continuing to serve underrepresented communities across California.
Expanding Phase I Clinical Trials Services
The expanded capabilities include the addition of new state of the art facilities, specialized staff, and innovative technology. FOMAT will now offer a full range of Phase I clinical trials services, including early phase clinical trials, pharmacokinetic and pharmacodynamic studies, and first-in-human trials.
Therapeutic Areas Covered
The clinic and site specific processes are designed to carry out simple and complex clinical trials, offered across multiple therapeutic specialties, including infectious diseases, vaccines, CNS, Autoimmune, Inflammation, Metabolic, Endocrinology, NAFLD, NASH, Obesity, and T2D clinical trials.
Conducting Phase I clinical trials across this broad range of specialties allows FOMAT to serve sponsors and CROs with diverse pipeline needs under one experienced research organization. Each therapeutic area is supported by dedicated clinical staff trained in early phase protocols, ensuring participant safety and data integrity at every stage of the study.
A Commitment to Diversity in Early Phase Research
“We are committed to providing our clients with the highest level of service and support, and the expansion of our Phase I clinical trials capabilities is a testament to that commitment,” said Nicholas Focil, CEO of FOMAT. “Patient Diversity has been core to our mission since founding the company. Bringing early phase trials to our underserved and underrepresented communities is key to true inclusion during drug development. To that end, we are excited to help facilitate better engagement with both industry and patients.”
FOMAT Medical Researchâs Early Phase/Phase One clinic is located just outside of Los Angeles, in Oxnard, California. It features state-of-the art facilities and marks a significant milestone in the companyâs service offering, covering all phases of clinical development, and bolsters its ongoing commitment to innovate healthcare through diversity.
Early phase research has historically excluded minority and underserved populations, resulting in clinical data that does not fully represent the diversity of real world patients. FOMAT addresses this gap directly by operating Phase I clinical trials in communities that are often overlooked by traditional research sites. This approach not only strengthens the scientific value of the data collected but also ensures that the benefits of medical innovation reach every patient, regardless of their background or zip code.
Phase I Clinical Trials Clinic Location
FOMAT’s Early Phase clinical trials clinic is located just outside of Los Angeles, in Oxnard, California. It features state of the art facilities and marks a significant milestone in the company’s service offering, covering all phases of clinical development, and bolsters its ongoing commitment to innovate healthcare through diversity.
Being based in Ventura County gives FOMAT direct access to one of California’s most ethnically diverse patient populations. This geographic advantage strengthens the quality and representativeness of Phase I clinical trials data collected at the site, making FOMAT a strategic partner for sponsors seeking inclusive early phase research.
About FOMATÂ
FOMA, headquartered in Oxnard, California, is an Embedded Research Organization (ERO), a subset of a Site Management Organization (SMO), focused on innovating healthcare with our high-quality services. With over 10 years of experience in participating in Phase 1 through Phase 4 clinical trials in a wide variety of therapeutic areas, we rely on a highly experienced clinical research team with the professional expertise necessary to assist Sponsors and Contract Research Organizations (CROs) with reaching their project goals quickly and effectively.
Contact Information:
If you want more information about our Phase 1 capabilities, please contact:
Brandon Johnson
Business Development Specialist